Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous tumor lysate-pulsed dendritic cell vaccine (Macarena De La Fuente)
- Development stage
- Discontinued
- Lead developer
- University of Miami
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This autologous dendritic cell vaccine is an investigational personalized immunotherapy developed for the treatment of malignant gliomas, including glioblastoma and anaplastic astrocytoma. The vaccine is produced by harvesting a patient's own peripheral blood mononuclear cells, differentiating them into dendritic cells, and pulsing them with autologous tumor lysate to present a broad spectrum of patient-specific tumor antigens. Administered intradermally, the vaccine is designed to prime the immune system to recognize and attack glioma cells. In clinical trials led by Dr. Macarena De La Fuente, the vaccine was used in a regimen that included the topical adjuvant imiquimod (a TLR7 agonist) and subsequent tumor lysate boosts to enhance the anti-tumor T-cell response.
- Other names
- Dendritic Cell VaccineDC VaccineAutologous Dendritic Cell Vaccinedendritic cell vaccine-Macarena De La Fuente, MD-malignant glioma-glioblastoma-anaplastic astrocytoma
Beyond the preview
Go deeper on Autologous tumor lysate-pulsed dendritic cell vaccine (Macarena De La Fuente).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous tumor lysate-pulsed dendritic cell vaccine (Macarena De La Fuente).